Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury

Rene Przkora, David Herndon, Donald J. Sherrard, David L. Chinkes, Gordon L. Klein

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) over placebo. We followed patients unblinded after 6 months every 3 months up to 2 years post-burn to see if the effects of pamidronate were sustained. Additionally, we assessed bone remodeling at 1 year post-burn by iliac crest bone biopsy. We enrolled 57 subjects who were initially randomized to pamidronate (n = 32) and placebo (n = 25). After 2 years, 21 subjects (pamidronate = 8, placebo = 13) remained. Analysis of bone densitometry by dual energy X-ray absorptiometry revealed an effect of both treatment (p < 0.012 for total body BMC, p < 0.001 for lumbar spine BMC, p < 0.014 for lumbar spine bone area and p < 0.003 for lumbar spine bone density (BMD)) and time (p < 0.0003 on total body BMC, p < 0.001 on lumbar spine BMC, p < 0.001 on lumbar spine bone area, and no significant difference on lumbar spine BMD). There was no interaction between treatment and time. Results for bone histomorphometry revealed no effect of treatment on either static or dynamic parameters but did show an effect of time on osteoid area (p = 0.004, surface p < 0.001, and width, p < 0.001). We conclude that acute administration of pamidronate resulted in sustained therapeutic effect on bone and that this type of administration may serve as a useful adjunct to other therapies in the preservation and augmentation of bone mass following severe burns.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalBone
Volume41
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

pamidronate
Bone Density
Spine
Pediatrics
Bone and Bones
Wounds and Injuries
Burns
Placebos
Densitometry
Bone Remodeling
Photon Absorptiometry
Therapeutic Uses
Therapeutics

Keywords

  • Bone density
  • Bone mineral content
  • Burns
  • Pamidronate

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. / Przkora, Rene; Herndon, David; Sherrard, Donald J.; Chinkes, David L.; Klein, Gordon L.

In: Bone, Vol. 41, No. 2, 08.2007, p. 297-302.

Research output: Contribution to journalArticle

Przkora, Rene ; Herndon, David ; Sherrard, Donald J. ; Chinkes, David L. ; Klein, Gordon L. / Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. In: Bone. 2007 ; Vol. 41, No. 2. pp. 297-302.
@article{c07a3f7b4b744f53abaacb504062eae2,
title = "Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury",
abstract = "We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) over placebo. We followed patients unblinded after 6 months every 3 months up to 2 years post-burn to see if the effects of pamidronate were sustained. Additionally, we assessed bone remodeling at 1 year post-burn by iliac crest bone biopsy. We enrolled 57 subjects who were initially randomized to pamidronate (n = 32) and placebo (n = 25). After 2 years, 21 subjects (pamidronate = 8, placebo = 13) remained. Analysis of bone densitometry by dual energy X-ray absorptiometry revealed an effect of both treatment (p < 0.012 for total body BMC, p < 0.001 for lumbar spine BMC, p < 0.014 for lumbar spine bone area and p < 0.003 for lumbar spine bone density (BMD)) and time (p < 0.0003 on total body BMC, p < 0.001 on lumbar spine BMC, p < 0.001 on lumbar spine bone area, and no significant difference on lumbar spine BMD). There was no interaction between treatment and time. Results for bone histomorphometry revealed no effect of treatment on either static or dynamic parameters but did show an effect of time on osteoid area (p = 0.004, surface p < 0.001, and width, p < 0.001). We conclude that acute administration of pamidronate resulted in sustained therapeutic effect on bone and that this type of administration may serve as a useful adjunct to other therapies in the preservation and augmentation of bone mass following severe burns.",
keywords = "Bone density, Bone mineral content, Burns, Pamidronate",
author = "Rene Przkora and David Herndon and Sherrard, {Donald J.} and Chinkes, {David L.} and Klein, {Gordon L.}",
year = "2007",
month = "8",
doi = "10.1016/j.bone.2007.04.195",
language = "English (US)",
volume = "41",
pages = "297--302",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury

AU - Przkora, Rene

AU - Herndon, David

AU - Sherrard, Donald J.

AU - Chinkes, David L.

AU - Klein, Gordon L.

PY - 2007/8

Y1 - 2007/8

N2 - We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) over placebo. We followed patients unblinded after 6 months every 3 months up to 2 years post-burn to see if the effects of pamidronate were sustained. Additionally, we assessed bone remodeling at 1 year post-burn by iliac crest bone biopsy. We enrolled 57 subjects who were initially randomized to pamidronate (n = 32) and placebo (n = 25). After 2 years, 21 subjects (pamidronate = 8, placebo = 13) remained. Analysis of bone densitometry by dual energy X-ray absorptiometry revealed an effect of both treatment (p < 0.012 for total body BMC, p < 0.001 for lumbar spine BMC, p < 0.014 for lumbar spine bone area and p < 0.003 for lumbar spine bone density (BMD)) and time (p < 0.0003 on total body BMC, p < 0.001 on lumbar spine BMC, p < 0.001 on lumbar spine bone area, and no significant difference on lumbar spine BMD). There was no interaction between treatment and time. Results for bone histomorphometry revealed no effect of treatment on either static or dynamic parameters but did show an effect of time on osteoid area (p = 0.004, surface p < 0.001, and width, p < 0.001). We conclude that acute administration of pamidronate resulted in sustained therapeutic effect on bone and that this type of administration may serve as a useful adjunct to other therapies in the preservation and augmentation of bone mass following severe burns.

AB - We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) over placebo. We followed patients unblinded after 6 months every 3 months up to 2 years post-burn to see if the effects of pamidronate were sustained. Additionally, we assessed bone remodeling at 1 year post-burn by iliac crest bone biopsy. We enrolled 57 subjects who were initially randomized to pamidronate (n = 32) and placebo (n = 25). After 2 years, 21 subjects (pamidronate = 8, placebo = 13) remained. Analysis of bone densitometry by dual energy X-ray absorptiometry revealed an effect of both treatment (p < 0.012 for total body BMC, p < 0.001 for lumbar spine BMC, p < 0.014 for lumbar spine bone area and p < 0.003 for lumbar spine bone density (BMD)) and time (p < 0.0003 on total body BMC, p < 0.001 on lumbar spine BMC, p < 0.001 on lumbar spine bone area, and no significant difference on lumbar spine BMD). There was no interaction between treatment and time. Results for bone histomorphometry revealed no effect of treatment on either static or dynamic parameters but did show an effect of time on osteoid area (p = 0.004, surface p < 0.001, and width, p < 0.001). We conclude that acute administration of pamidronate resulted in sustained therapeutic effect on bone and that this type of administration may serve as a useful adjunct to other therapies in the preservation and augmentation of bone mass following severe burns.

KW - Bone density

KW - Bone mineral content

KW - Burns

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=34347238909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347238909&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2007.04.195

DO - 10.1016/j.bone.2007.04.195

M3 - Article

VL - 41

SP - 297

EP - 302

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -